One million exomes identify FNIP1 as a metabolic brake.

Exome sequencing of more than 1 million people uncovered dozens of genes linked to the biomarker of the body's energy state (Hindy et al.). Rare loss-of-function variants in FNIP1, a suppressor of mitochondrial energy expenditure, were associated with lower cardiometabolic disease risk, nominating selective FNIP1 inhibition as a therapeutic strategy.